Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF Summary
Accession # P78410-1
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 200 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
2 μg/lane of Recombinant Human BTN3A2 His-tag Avi-tag (Catalog # AVI9514) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 27-37 kDa.
When Sheep Anti-Human BTN3A1/2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7136) is immobilized at 1.0 µg/mL, 100 µL/well, the concentration of Biotinylated Recombinant Human BTN3A2 His-tag Avi-tag (Catalog # AVI9514) that produces 50% of the optimal binding response is approximately 15-75 ng/mL.
BTN3A2 (Butyrophilin subfamily 3 member A2; also BTF3 and BT3.2) is a 36 kDa (predicted) glycoprotein, member of the BTN family, Ig Superfamily of molecules. It is postulated to be expressed on immune-related cells, as it has a structural similarity to MHC and CD80/CD86 molecules. Mature human BTN3A2 is a 305 amino acid (aa) type I transmembrane protein. It contains a 219 aa extracellular region with one V-type Ig-like domain and a 65 aa cytoplasmic tail. The cytoplasmic region undergoes phosphorylation on two serines. There are three potential splice forms. A rodent counterpart to BTN3A2 has not been reported. BTN3A2 mRNA over‑expression was associated with a good prognosis in relation to disease-free and overall survival in a cohort of 55 epithelial ovarian cancer (EOC) patients (1). Another study in a larger cohort of 199 high-grade EOC patients further confirmed that the protein expression of BTN3A2 in ovarian cancer tissues is positively correlated with the intraepithelial infiltration of CD4+ and CD8+ T cells (2), suggesting that BTN3A2 was a co-stimulatory molecule to modulate the infiltration of immune cells and thus the anti-cancer immunity. In consistent with previous publications, our in-house studies on BTN3A2 showed that BTN3A2 co-stimulated anti‑CD3 induced IFN-gamma secretion on CD3+ cells.
- LePage C., et al. Cancer Epidemiol Biomarkers Prev (2008) 17:913.
- LePage C., et al. PLoSOne (2012) 7:e38541.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF and earn rewards!
Have you used Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image